YD Bio Limited (YDES)
NASDAQ: YDESHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
YDES stock chart
Technical analysisKey statistics
All statistics- Market cap
- $342.12M
- EPS (TTM)
- -$0.04
- Dividend yield
- None
- 52-week range
- 1.70 – 15.72
- Day range
- 4.36 – 4.95
- Volume / Avg
- 29.79K / 309.22K
- Beta
- —
- Shares outstanding
- 70.83M
52-week range
YDES stock today
YD Bio (YDES) closed at $4.83 on Nov 20, up 5.92% (+$0.27), versus the S&P 500's 3.70% decline. Trading was light, with 29.79K shares changing hands, about 10% of the average daily volume. Shares are 69.3% below their 52-week high of $15.72, set on Dec 8, 2025 and 184.1% above the 52-week low of $1.70, in the middle of the past year's range.
YDES is down 60.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 42.8%. YD Bio has posted a net loss over the last twelve months (EPS of -$0.04), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About YD Bio
Company profileYD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma. It also provides Hydrogel (Hioxifilcon A) Soft (Hydrophilic) Contact Lens, a spherical and aspherical lenses.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Dr. Ethan Shen Ph.D.
- Headquarters
- Taipei
- Employees
- 13
- Website
- ydesgroup.com
Financial highlights
Full financialsIn fiscal 2025, YD Bio generated $596,817 in revenue, up 16.9% from fiscal 2024, its 2nd consecutive year of revenue growth. YD Bio reported a net loss of $8.3 million, compared with a loss of $1.4 million a year earlier. Gross margin was 28.1% (down from 30.4%) and operating margin -883.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $596.82K | $510.36K | $350.13K |
| Growth | +16.94% | +45.76% | — |
| Net income | $-8.31M | $-1.41M | $13.56K |
| EPS (diluted) | $-0.12 | $-0.02 | $0.00 |
YDES news
All YDES news- YD Bio Expects FDA Feedback On Dry Eye Candidate By January 4, 2027NasdaqYDES, ET
- YD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye DiseaseGlobeNewswire
- YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness ProgramsGlobeNewswire
YD Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TLSITriSalus Life Sciences Inc. | 2.32 | +6.67% | $143.14M | vs YDES |
| BNRBurning Rock Biotech Limited ADR | 13.24 | -0.60% | $139.63M | vs YDES |
| KEQUKewaunee Scientific Corporation | 33.55 | -2.75% | $97.14M | vs YDES |
| XGNExagen Inc. | 3.61 | -5.00% | $92.10M | vs YDES |
| BDSXBiodesix Inc. | 7.56 | -8.92% | $83.83M | vs YDES |
| SERASera Prognostics Inc. Class A | 1.81 | -4.23% | $71.98M | vs YDES |
| FLGTFulgent Genetics Inc. | 24.12 | -2.66% | $673.89M | vs YDES |
| MDXHMDxHealth SA | 0.1074 | -8.52% | $10.25M | vs YDES |
Indexes, lists and sector
YD Bio stock FAQ
What is YD Bio's stock price today?
YDES last traded at $4.83 as of Nov 20, 4:00 PM EST, up 5.92% on the day. Prices are delayed at least 15 minutes.
Who is YD Bio's CEO?
Dr. Ethan Shen Ph.D. is the chief executive officer of YD Bio Limited, which has about 13 employees.
What is the YDES 52-week high?
The 52-week high for YDES is $15.72 and the 52-week low is $1.70. The stock is currently 69.3% below its high.